DrugPatentWatch Database Preview
VILTEPSO Drug Patent Profile
Email this page to a colleague
Which patents cover Viltepso, and when can generic versions of Viltepso launch?
Viltepso is a drug marketed by Nippon Shinyaku and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-one patent family members in twenty countries.
The generic ingredient in VILTEPSO is viltolarsen. Additional details are available on the viltolarsen profile page.
DrugPatentWatch® Generic Entry Outlook for Viltepso
Viltepso will be eligible for patent challenges on August 12, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 31, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for VILTEPSO
| International Patents: | 51 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| What excipients (inactive ingredients) are in VILTEPSO? | VILTEPSO excipients list |
| DailyMed Link: | VILTEPSO at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VILTEPSO
Generic Entry Date for VILTEPSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for VILTEPSO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ⤷ Try it Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VILTEPSO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Slovenia | 2612917 | ⤷ Try it Free |
| Slovenia | 3018211 | ⤷ Try it Free |
| Russian Federation | 2567664 | ⤷ Try it Free |
| San Marino | T201600111 | ⤷ Try it Free |
| Japan | WO2012029986 | ⤷ Try it Free |
| World Intellectual Property Organization (WIPO) | 2012029986 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
